Related Experiment Video
Updated: Aug 12, 2026

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance
Published on: December 28, 2017
Resistance mechanisms in clinical isolates of Candida albicans
Theodore C White1, Scott Holleman, Francis Dy
1Department of Pathobiology, School of Public Health and Community Medicine, University of Washington, Seattle, Washington 98109-1651, USA. tedwhite@u.washington.edu
Abstract:
Resistance to azole antifungals continues to be a significant problem in the common fungal pathogen Candida albicans. Many of the molecular mechanisms of resistance have been defined with matched sets of susceptible and resistant clinical isolates from the same strain. Mechanisms that have been identified include alterations in the gene encoding the target enzyme ERG11 or overexpression of efflux pump genes including CDR1, CDR2, and MDR1. In the present study, a collection of unmatched clinical isolates of C. albicans was analyzed for the known molecular mechanisms of resistance by standard methods. The collection was assembled so that approximately half of the isolates were resistant to azole drugs. Extensive cross-resistance was observed for fluconazole, clotrimazole, itraconazole, and ketoconazole. Northern blotting analyses indicated that overexpression of CDR1 and CDR2 correlates with resistance, suggesting that the two genes may be coregulated. MDR1 overexpression was observed infrequently in some resistant isolates. Overexpression of FLU1, an efflux pump gene related to MDR1, did not correlate with resistance, nor did overexpression of ERG11. Limited analysis of the ERG11 gene sequence identified several point mutations in resistant isolates; these mutations have been described previously. Two of the most common point mutations in ERG11 associated with resistance, D116E and E266D, were tested by restriction fragment length polymorphism analysis of the isolates from this collection. The results indicated that the two mutations occur frequently in different isolates of C. albicans and are not reliably associated with resistance. These analyses emphasize the diversity of mechanisms that result in a phenotype of azole resistance. They suggest that the resistance mechanisms identified in matched sets of susceptible and resistant isolates are not sufficient to explain resistance in a collection of unmatched clinical isolates and that additional mechanisms have yet to be discovered.
Insights
Mechanisms of azole antifungal resistance in Candida albicans are diverse. Known resistance genes like ERG11 and efflux pumps CDR1/CDR2 are not always linked to resistance in clinical isolates, suggesting unknown factors contribute.
Area of Science:
- Mycology
- Antimicrobial Resistance
Background:
- Azole antifungals are crucial for treating Candida albicans infections.
- Mechanisms of azole resistance, including ERG11 mutations and efflux pump overexpression (CDR1, CDR2, MDR1), are known from matched isolates.
- Unmatched clinical isolates present a challenge in understanding resistance mechanisms.
Purpose of the Study:
- To investigate known molecular mechanisms of azole antifungal resistance in a collection of unmatched Candida albicans clinical isolates.
- To determine the correlation between specific gene alterations and azole resistance phenotypes.
- To identify potential novel resistance mechanisms in clinical settings.
Main Methods:
- Analysis of a collection of unmatched Candida albicans clinical isolates, with approximately half being azole-resistant.
- Standard methods including Northern blotting to assess gene expression (CDR1, CDR2, MDR1, FLU1).
- Restriction fragment length polymorphism (RFLP) analysis to detect specific ERG11 point mutations (D116E, E266D).
Main Results:
- Extensive cross-resistance observed among fluconazole, clotrimazole, itraconazole, and ketoconazole.
- Overexpression of CDR1 and CDR2 correlated with resistance, suggesting coregulation.
- MDR1 overexpression was infrequent; FLU1 overexpression did not correlate with resistance. ERG11 overexpression was not observed.
- Common ERG11 mutations (D116E, E266D) were frequent but not reliably associated with resistance in this cohort.
Conclusions:
- Known resistance mechanisms identified in matched isolates are insufficient to explain azole resistance in diverse, unmatched clinical isolates.
- The study highlights the heterogeneity of azole resistance mechanisms in Candida albicans.
- Additional, yet undiscovered, mechanisms likely contribute to azole resistance in clinical settings.
Related Concept Videos
Treatment Resistant Cancers
Development of Antibiotic Resistance
Mechanism of Antibiotic Resistance in MRSA
Candidiasis
Antifungal Agents
Clinical Significance of Antibiotic Resistance

